Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Yun Lan, Linghua Li, Weilie Chen, Xizi Deng, Junbin Li, Qinghong Fan, Xiaoli Cai, Weiping Cai & Fengyu Hu. (2020) Absence of Integrase Inhibitor-Associated Resistance Among Antiretroviral Therapy-Naïve HIV-1-Infected Adults in Guangdong Province, China, in 2018. Infection and Drug Resistance 13, pages 4389-4394.
Read now
Read now
Rosa de Miguel, Rocio Montejano, Natalia Stella-Ascariz & Jose R. Arribas. (2018) A safety evaluation of raltegravir for the treatment of HIV. Expert Opinion on Drug Safety 17:2, pages 217-223.
Read now
Read now
Jose Vicente Fernandez-Montero, Pablo Barreiro, Pablo Labarga, Carmen De Mendoza & Vicente Soriano. (2014)
Dolutegravir, abacavir and lamivudine as HIV therapy. Expert Opinion on Pharmacotherapy 15:7, pages 1051-1057.
Read now
Read now
Articles from other publishers (22)
Haidong Lu, Stephen R Cole, Daniel Westreich, Michael G Hudgens, Adaora A Adimora, Keri N Althoff, Michael J Silverberg, Kate Buchacz, Jun Li, Jessie K Edwards, Peter F Rebeiro, Viviane D Lima, Vincent C Marconi, Timothy R Sterling, Michael A Horberg, M John Gill, Mari M Kitahata, Joseph J Eron & Richard D Moore. (2021) Clinical Effectiveness of Integrase Strand Transfer Inhibitor–Based Antiretroviral Regimens Among Adults With Human Immunodeficiency Virus: A Collaboration of Cohort Studies in the United States and Canada. Clinical Infectious Diseases 73:7, pages e1408-e1414.
Crossref
Crossref
Robin M. Nance, Vani Vannappagari, Kimberly Smith, Catherine B. Johannes, Brian Calingaert, Catherine W. Saltus, Kenneth H. Mayer, Bridget M. Whitney, Benigno Rodriguez, Richard D. Moore, Joseph J. Eron, Elvin Geng, William Christopher Mathews, Michael J. Mugavero, Michael S. Saag, Mari M. Kitahata, Joseph A. C. Delaney & Heidi M. Crane. (2019) Virologic Failure Among People Living With HIV Initiating Dolutegravir-Based Versus Other Recommended Regimens in Real-World Clinical Care Settings. JAIDS Journal of Acquired Immune Deficiency Syndromes 81:5, pages 572-577.
Crossref
Crossref
S Modica, B Rossetti, F Lombardi, F Lagi, M Maffeo, R D'Autilia, M Pecorari, I Vicenti, B Bruzzone, G Magnani, S Paolucci, D Francisci, G Penco, D Sacchini, M Zazzi, A De Luca & A Di Biagio. (2019) Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort. HIV Medicine 20:2, pages 137-146.
Crossref
Crossref
Joseph Magagnoli, S. Scott Sutton, James W. Hardin & Babatunde Edun. (2018) Longitudinal trends in base antiretroviral therapy utilization for human immunodeficiency virus from 2000 to 2016. JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY 2:1, pages 32-39.
Crossref
Crossref
Robin M. NanceJ.A. Chris DelaneyJane M. SimoniIra B. WilsonKenneth H. MayerBridget M. WhitneyFrances M. AunonSteven A. SafrenMichael J. MugaveroW. Christopher MathewsKaterina A. ChristopoulosJoseph J. EronSonia NapravnikRichard D. MooreBenigno RodriguezBryan LauRob J. FredericksenMichael S. SaagMari M. KitahataHeidi M. Crane. (2018) HIV Viral Suppression Trends Over Time Among HIV-Infected Patients Receiving Care in the United States, 1997 to 2015. Annals of Internal Medicine 169:6, pages 376.
Crossref
Crossref
Bluma G. Brenner & Mark A. Wainberg. (2017) Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance. Virus Research 239, pages 1-9.
Crossref
Crossref
Sui-Yuan Chang, Pi-Han Lin, Chien-Lin Cheng, Mao-Yuan Chen, Hsin-Yun Sun, Szu-Min Hsieh, Wang-Huei Sheng, Yi-Ching Su, Li-Hsin Su, Shu-Fang Chang, Wen-Chun Liu, Chien-Ching Hung & Shan-Chwen Chang. (2016) Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in Taiwan. Scientific Reports 6:1.
Crossref
Crossref
M Jaeckle, P Khaykin, A Haberl, P De Leuw, G Schüttfort, C Stephan & T Wolf. (2016) Efficacy of raltegravir-containing regimens in antiretroviral-naïve and -experienced individuals in routine clinical practice. International Journal of STD & AIDS 27:13, pages 1170-1179.
Crossref
Crossref
Steve Kanters, Marco Vitoria, Meg Doherty, Maria Eugenia Socias, Nathan Ford, Jamie I Forrest, Evan Popoff, Nick Bansback, Sabin Nsanzimana, Kristian Thorlund & Edward J Mills. (2016) Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. The Lancet HIV 3:11, pages e510-e520.
Crossref
Crossref
Josep M. Llibre, Sharon Walmsley & Josep M. Gatell. (2016) Backbones versus core agents in initial ART regimens: one game, two players. Journal of Antimicrobial Chemotherapy 71:4, pages 856-861.
Crossref
Crossref
Kristen N. Andreatta, Michael D. Miller & Kirsten L. White. (2016) Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions. Antimicrobial Agents and Chemotherapy 60:2, pages 757-765.
Crossref
Crossref
Hong Xiao, Yile Xue, Shiming Gu, Jiangrong Wang, Hongqing Sun & Hongzhou Lu. (2016) Efficacy and safety of antiretroviral regimens including raltegravir to treat HIV-infected patients with hemophilia. BioScience Trends 10:1, pages 42-46.
Crossref
Crossref
Nicole Hassoun. (2015) The Global Health Impact Index: Promoting Global Health. PLOS ONE 10:12, pages e0141374.
Crossref
Crossref
Margherita Bracchi & Anton Pozniak. (2015) Observing the revolution: A commentary on the new GeSIDA HIV guidelines. Enfermedades Infecciosas y Microbiología Clínica 33:8, pages 505-507.
Crossref
Crossref
Kristen N. Andreatta, Derrick D. Goodman, Michael D. Miller & Kirsten L. White. (2015) Reduced Viral Fitness and Lack of Cross-Class Resistance with Integrase Strand Transfer Inhibitor and Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations. Antimicrobial Agents and Chemotherapy 59:6, pages 3441-3449.
Crossref
Crossref
Giordano Madeddu, Giuseppe V.L. De Socio, Elena Ricci, Tiziana Quirino, Giancarlo Orofino, Laura Carenzi, Marco Franzetti, Giustino Parruti, Canio Martinelli, Francesca Vichi, Giovanni Penco, Chiara Dentone, Benedetto Maurizio Celesia, Paolo Maggi, Raffaella Libertone, Paola Bagella, Antonio Di Biagio & Paolo Bonfanti. (2015) Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance. International Journal of Antimicrobial Agents 45:3, pages 289-294.
Crossref
Crossref
Paula Mendes Luz, Mathias Bruyand, Sayonara Ribeiro, Fabrice Bonnet, Ronaldo Ismério Moreira, Mojgan Hessamfar, Dayse Perreira Campos, Carine Greib, Charles Cazanave, Valdilea Gonçalves Veloso, François Dabis, Beatriz Grinsztejn & Geneviève Chêne. (2014) AIDS and non-AIDS severe morbidity associated with hospitalizations among HIV-infected patients in two regions with universal access to care and antiretroviral therapy, France and Brazil, 2000–2008: hospital-based cohort studies. BMC Infectious Diseases 14:1.
Crossref
Crossref
M. Pollicita, M. Surdo, F. Di Santo, M. F. Cortese, L. Fabeni, V. Fedele, I. Malet, A.-G. Marcelin, V. Calvez, F. Ceccherini-Silberstein, C. F. Perno & V. Svicher. (2014) Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes. Journal of Antimicrobial Chemotherapy 69:9, pages 2412-2419.
Crossref
Crossref
Sayonara R Ribeiro, Paula M Luz, Dayse P Campos, Ronaldo I Moreira, Lara Coelho, André Japiassu, Fernando Bozza, Valdilea G Veloso, Genevieve Chene & Beatriz Grinsztejn. (2013) Incidence and Determinants of Severe Morbidity among HIV-Infected Patients from Rio De Janeiro, Brazil, 2000–2010. Antiviral Therapy 19:4, pages 387-397.
Crossref
Crossref
Jürgen K. Rockstroh, Edwin DeJesus, Jeffrey L. Lennox, Yazdan Yazdanpanah, Michael S. Saag, Hong Wan, Anthony J. Rodgers, Monica L. Walker, Michael Miller, Mark J. DiNubile, Bach-Yen Nguyen, Hedy Teppler, Randi Leavitt & Peter Sklar. (2013) Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 63:1, pages 77-85.
Crossref
Crossref
Peter Messiaen, Annemarie M. J. Wensing, Axel Fun, Monique Nijhuis, Nele Brusselaers & Linos Vandekerckhove. (2013) Clinical Use of HIV Integrase Inhibitors: A Systematic Review and Meta-Analysis. PLoS ONE 8:1, pages e52562.
Crossref
Crossref
Anna Maria Geretti, Daniele Armenia & Francesca Ceccherini-Silberstein. (2012) Emerging patterns and implications of HIV-1 integrase inhibitor resistance. Current Opinion in Infectious Diseases 25:6, pages 677-686.
Crossref
Crossref